2026 Rankings
Best Biological Age Tests Ranked 2026
The 8 best biological age tests for 2026 ranked by scientific validity, decision utility, repeatability, and cost. TruAge Complete (Trudiagnostic) leads as the gold standard epigenetic test with DunedinPACE and 13+ validated clocks. PhenoAge calculated from standard bloodwork is the essential free complement. GlycanAge measures the inflammation-axis biological age with superior lifestyle intervention sensitivity. Elysium Index provides accessible epigenetic testing at a lower price point. InsideTracker InnerAge 2.0 is the most actionable option with full blood panel and personalized recommendations. The omega-3 index is the cheapest biological age proxy with direct supplementation intervention. Telomere testing adds independent cellular senescence signal for advanced monitoring. Free calculators provide a zero-cost starting point for anyone with existing bloodwork.
Quick Picks
TruAge Complete (Trudiagnostic) — Epigenetic Methylation Panel
Longevity-focused individuals who want the most comprehensive and scientifically validated biological age readout available to consumers — including DunedinPACE (pace of aging), PCGTAge, GrimAge2, and 13+ epigenetic clock algorithms on a single blood spot sample
Phenotypic Age (LevineAge / PhenoAge) — Blood Biomarker Score
Anyone who has already had a standard blood panel and wants to calculate a validated biological age estimate for free — PhenoAge uses 9 standard biomarkers already included in most longevity blood panels to generate a biological age score with strong mortality and disease predictive validity
GlycanAge — IgG Glycomics Biological Age Test
Longevity-focused users who want a biological age test that is mechanistically independent from epigenetic and blood biomarker tests — GlycanAge measures the glycan composition of IgG antibodies, an independent biological age signal with strong clinical validation and exceptional sensitivity to lifestyle interventions including exercise, diet, and HRT
Best Biological Age Tests 2026 — Ranked by Validity, Utility & Cost
| Rank | Protocol | Difficulty | Effectiveness | Best For |
|---|---|---|---|---|
| #1 | TruAge Complete (Trudiagnostic) — Epigenetic Methylation Panel | 3/10 | 9.6/10 | Longevity-focused individuals who want the most comprehensive and scientifically validated biological age readout available to consumers — including DunedinPACE (pace of aging), PCGTAge, GrimAge2, and 13+ epigenetic clock algorithms on a single blood spot sample |
| #2 | Phenotypic Age (LevineAge / PhenoAge) — Blood Biomarker Score | 2/10 | 8.8/10 | Anyone who has already had a standard blood panel and wants to calculate a validated biological age estimate for free — PhenoAge uses 9 standard biomarkers already included in most longevity blood panels to generate a biological age score with strong mortality and disease predictive validity |
| #3 | GlycanAge — IgG Glycomics Biological Age Test | 3/10 | 8.5/10 | Longevity-focused users who want a biological age test that is mechanistically independent from epigenetic and blood biomarker tests — GlycanAge measures the glycan composition of IgG antibodies, an independent biological age signal with strong clinical validation and exceptional sensitivity to lifestyle interventions including exercise, diet, and HRT |
| #4 | Elysium Index — Second-Generation Epigenetic Clock | 3/10 | 8.2/10 | Longevity-focused adults seeking an accessible, peer-reviewed epigenetic biological age test at a lower price point than TruAge Complete — Elysium Index uses a validated second-generation epigenetic clock algorithm and provides clear, actionable biological age comparison with annual retesting subscription options |
| #5 | InsideTracker Ultimate + InnerAge 2.0 — Biomarker Biological Age with Action Plan | 4/10 | 7.8/10 | Action-oriented longevity users who want a comprehensive blood panel alongside a biological age score and prefer a system that translates every biomarker into a specific, personalized intervention recommendation — InsideTracker is the most behaviorally actionable biological age platform available |
| #6 | Omega-3 Index (OmegaQuant) — Telomere-Correlated Longevity Biomarker | 1/10 | 7.2/10 | Longevity-focused users who want the most affordable and directly actionable biological age proxy — the omega-3 index at the 8–12% range correlates with approximately 5 years younger biological age by telomere length and is directly improved by a specific supplement protocol, making it the cheapest longevity biomarker with a clear intervention path |
| #7 | Telomere Length Testing (Life Length / RepeatDX / SpectraCell) | 3/10 | 6.8/10 | Longevity researchers and advanced biohackers who want a direct cellular aging measurement independent of epigenetic and blood biomarker methods — telomere length provides a distinct biological aging signal reflecting cumulative cellular senescence burden, though it has significant measurement variability that limits single-test interpretability |
| #8 | Free Biological Age Calculators (Aging.ai, PhenoAge Tools, MyHealthInsights) | 1/10 | 5.8/10 | Complete beginners to biological age testing who want a free starting estimate from existing bloodwork — free online biological age calculators like Aging.ai 3.0 and the PhenoAge spreadsheet tools provide a validated first approximation that costs nothing and can be run in minutes from a standard blood panel |
Research Context
Your chronological age is a clock. Your biological age is a report card. These two numbers can diverge by 15 years or more — in either direction — depending on genetics, lifestyle, metabolic health, and how consistently you've run the interventions that actually slow cellular aging. The question is no longer whether biological age testing is real science. The DunedinPACE epigenetic clock has been independently validated in five major longitudinal cohorts. PhenoAge is used as a standard comparator in published aging research. GlycanAge detects measurable biological age improvement within 6 months of lifestyle change. Biological age testing has crossed the threshold from biohacker novelty to evidence-based longevity monitoring.
The challenge is choosing the right test for your situation. Epigenetic DNA methylation tests (TruAge, Elysium) measure biological aging at the molecular level — the same technology used in the academic papers Bryan Johnson, David Sinclair, and Rhonda Patrick reference in their longevity protocols. Blood biomarker scores (PhenoAge, InsideTracker) are faster and cheaper but measure current physiological state rather than a true molecular aging clock. Glycan tests (GlycanAge) measure the inflammatory aging axis specifically and respond faster to lifestyle changes than methylation clocks. Telomere tests measure cellular senescence burden directly but have high measurement noise on single tests. Each method captures a different axis of biological aging.
This ranking evaluates all major biological age testing approaches on scientific validity, decision utility, repeatability, cost, and what a positive result actually tells you. The top-ranked tests are not necessarily the most expensive — they are the ones where the result changes what you do next. A test that costs $400 but produces an uninterpretable number is less valuable than a free PhenoAge calculation that immediately points to a glucose or inflammation problem you can fix this week. We score accordingly.
The ideal biological age monitoring protocol uses complementary tests: a comprehensive epigenetic test (TruAge) once per year for the highest-resolution aging readout, PhenoAge calculated quarterly from routine bloodwork as a free intermediate check, and GlycanAge every 6 months as an inflammation-axis lifestyle intervention tracker. The omega-3 index is the cheapest gateway biomarker — most adults test at 4–6% when the longevity-protective range is 8–12%, and fixing this single number with a $50 test and a well-dosed EPA+DHA supplement is among the highest-return longevity investments available in 2026.
For adjacent supplement research and deeper ingredient context, continue with these related sister-site resources: Alive Longevity: Longevity Supplement Guides and Peaked Labs: TRT Provider Comparisons.
For peptide-specific protocols, visit peakedlabs.com. For longevity deep-dives, visit alivelongevity.com.
How We Ranked These Protocols
Our editorial methodology for biological age tests compares evidence quality, applicability, downside risk, implementation burden, and the relevance of outcomes such as scientific validity of the underlying algorithm, sensitivity to lifestyle interventions, decision utility of the result, repeatability, and cost efficiency per insight delivered. These dimensions help organize the literature; they are not a validated clinical prediction model.
Randomized controlled trials and systematic reviews generally provide stronger causal evidence than mechanism studies, uncontrolled observations, anecdotes, or surrogate markers. We also look for whether the studied population, formulation, dose, comparator, and outcome match the claim being made.
Practical burden matters because an intervention that is difficult, expensive, or hard to monitor may be less useful even when the biological rationale is plausible. We heavily weighted independent third-party validation — tests where the underlying algorithm has been confirmed in published studies outside the company that sells it score significantly higher than tests that rely primarily on internal validation data. DunedinPACE's validation across 5+ independent longitudinal cohorts earned TruAge Complete the top position. PhenoAge's Cell Metabolism publication and UK Biobank validation earned it the #2 position despite being free. We also evaluated the 'action gap': what specific health behavior does a positive result enable? Tests that produce a single number without actionable follow-through score lower than tests that point to specific interventions. Any numeric or ordinal ordering on ProtocolRank should be interpreted as editorial prioritization, not a quantified probability of benefit.
Finally, each option sits inside a broader medical and behavioral context. Sleep, nutrition, training, medications, comorbidities, and clinician-supervised care can change both the expected benefit and the risk. The comparison should narrow the questions worth asking; it should not replace individualized review where that review is appropriate.
Detailed Protocol Breakdowns
TruAge Complete (Trudiagnostic) — Epigenetic Methylation Panel
The current gold standard in consumer biological age testing — TruAge Complete runs a DNA methylation array on a dried blood spot and reports 13+ epigenetic clocks, including DunedinPACE (the best-validated pace-of-aging biomarker), PCGTAge, GrimAge2, and FitAge, alongside immune aging metrics and phenotypic age.
Best for: Longevity-focused individuals who want the most comprehensive and scientifically validated biological age readout available to consumers — including DunedinPACE (pace of aging), PCGTAge, GrimAge2, and 13+ epigenetic clock algorithms on a single blood spot sample
Pros
- +The most scientifically comprehensive consumer biological age test available — 13+ validated clock algorithms on one sample
- +DunedinPACE is the best-validated pace-of-aging biomarker, confirmed across multiple independent longitudinal cohorts
- +Uses the same 850K Illumina methylation array as the majority of published aging research — scientifically comparable
- +Immune aging panel provides additional senescence and inflammation insight beyond chronological age estimation
- +Fingerstick blood spot collection — no clinic visit required
- +Dashboard compares your results to a large reference population with clear interpretation guidance
Cons
- −Premium price point ($350–500) makes frequent retesting expensive
- −3–6 week turnaround for results is slower than blood panel-based scoring
- −Multiple clock numbers can be confusing without guidance on which to prioritize (answer: DunedinPACE)
- −Requires fingerstick blood collection — a minor barrier for needle-averse users
Protocol Analysis
TruAge Complete (Trudiagnostic) — Epigenetic Methylation Panel appears at editorial position #1 because its proposed mechanism is quantifying genome-wide DNA methylation patterns across 850,000+ CpG sites — the most information-rich molecular signal currently available for biological age estimation — then applying multiple validated clock algorithms to generate individual scores for overall epigenetic age, pace of aging, immune senescence, and health outcome risk stratification. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for TruAge Complete (Trudiagnostic) — Epigenetic Methylation Panel is: exceptionally strong — DunedinPACE is the best-validated biological aging rate biomarker, having been independently confirmed in multiple longitudinal cohorts including the Dunedin Study, CALERIE caloric restriction trial, and INTERVENE large biobank consortium; GrimAge2 predicts mortality and disease onset better than any other single aging biomarker in multi-study validation; the methylation array underlying TruAge is the same 850K Illumina array used in the majority of published epigenetic aging research, providing direct comparability to the scientific literature. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for TruAge Complete (Trudiagnostic) — Epigenetic Methylation Panel are: receiving multiple conflicting clock estimates without context creates confusion — GrimAge may differ from HorvathAge by 5+ years, which is normal and expected because the clocks measure different aspects of aging biology; the most actionable number is DunedinPACE, not the raw biological age difference; TruAge requires a blood spot collection and a 3–6 week wait for results, which is slower than some competing services. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: longevity-focused adults who want to measure actual biological aging rate, track the impact of specific protocols (caloric restriction, supplementation, lifestyle changes), and have a scientifically grounded comparison point for their epigenetic health beyond standard blood panels. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Phenotypic Age (LevineAge / PhenoAge) — Blood Biomarker Score
Dr. Morgan Levine's PhenoAge algorithm converts 9 standard blood biomarkers (albumin, creatinine, glucose, CRP, lymphocyte %, MCV, RDW, ALP, and WBC) into a validated biological age estimate — freely calculable from any standard blood panel and proven to predict mortality risk, disease onset, and healthspan in large epidemiological studies.
Best for: Anyone who has already had a standard blood panel and wants to calculate a validated biological age estimate for free — PhenoAge uses 9 standard biomarkers already included in most longevity blood panels to generate a biological age score with strong mortality and disease predictive validity
Pros
- +Free to calculate from standard blood panel biomarkers — zero additional test cost
- +Strong scientific validation across multiple large independent cohorts including UK Biobank and NHANES
- +Can be tracked quarterly alongside routine bloodwork — highest retest frequency of any biological age method
- +Reflects genuine multi-system biological aging: immune, metabolic, inflammatory, renal, and hepatic
- +Developed by a leading aging researcher (Morgan Levine) and widely used as a scientific comparator
- +Immediately actionable — biomarkers like glucose, CRP, and albumin have known lifestyle interventions
Cons
- −Less mechanistically specific than epigenetic clocks — reflects current blood chemistry state rather than a true molecular aging clock
- −Volatile in short-term illness or injury (especially CRP component)
- −Requires 9 specific biomarkers — some standard panels miss one or two (especially RDW or ALP)
- −Does not measure epigenetic aging directly — cannot detect longevity interventions that operate at the methylation level without affecting blood chemistry
Protocol Analysis
Phenotypic Age (LevineAge / PhenoAge) — Blood Biomarker Score appears at editorial position #2 because its proposed mechanism is aggregating 9 routine blood biomarkers that collectively reflect metabolic function, immune status, inflammation, red blood cell health, and organ function into a composite biological age score using a validated parametric model derived from the NHANES III and IV datasets — providing a phenotypic biological age estimate that captures multi-system aging physiology without requiring epigenetic or genomic testing. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Phenotypic Age (LevineAge / PhenoAge) — Blood Biomarker Score is: very strong for a free tool — the PhenoAge algorithm was developed by Levine et al. (2018) in Cell Metabolism using NHANES data and has since been validated in multiple independent cohorts including UK Biobank, the Framingham Heart Study, and numerous longevity cohorts; PhenoAge predicts all-cause mortality, multimorbidity, and physical function decline with effect sizes comparable to more expensive epigenetic clocks; the algorithm is now widely used in academic aging research as a standard comparator. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Phenotypic Age (LevineAge / PhenoAge) — Blood Biomarker Score are: PhenoAge is only as accurate as the blood panel it is calculated from — transient elevations from recent infection, acute illness, or lab timing variation will shift the score temporarily; the score reflects immune and metabolic state at time of draw, not a fixed biological clock; CRP is the most volatile component — a recent illness or injury can inflate PhenoAge by 3–5 years transiently. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: adults who want a free, scientifically validated biological age estimate from bloodwork they already have or plan to order; particularly useful as the most cost-effective monitoring tool for tracking how lifestyle, supplement, and nutrition protocols affect biological aging between more expensive epigenetic tests. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
GlycanAge — IgG Glycomics Biological Age Test
GlycanAge measures the pattern of sugar chains (glycans) attached to IgG antibodies — the primary immunoglobulin in blood — to generate a biological age score. The glycome changes measurably with aging and responds faster than most other biological age biomarkers to lifestyle changes, making it an ideal lifestyle intervention tracker.
Best for: Longevity-focused users who want a biological age test that is mechanistically independent from epigenetic and blood biomarker tests — GlycanAge measures the glycan composition of IgG antibodies, an independent biological age signal with strong clinical validation and exceptional sensitivity to lifestyle interventions including exercise, diet, and HRT
Pros
- +Mechanistically independent from epigenetic and blood biomarker tests — adds genuine information not captured elsewhere
- +Among the most sensitive biological age tests for lifestyle intervention response — responds faster to diet, exercise, and HRT than methylation clocks
- +Strong clinical validation including randomized controlled trial data in women (Mediterranean diet, HRT response)
- +Measures the inflammaging axis directly via IgG glycan composition — a distinct and validated aging mechanism
- +Fingerstick blood spot collection — no clinic required
- +Actionable lifestyle feedback provided with results
Cons
- −Measures one axis of biological aging (immune/inflammatory) rather than providing a comprehensive multi-axis biological age
- −Less internationally distributed than TruAge or Elysium
- −3–4 week turnaround
- −Results can reflect short-term inflammatory changes (illness, injury) as well as true biological aging trends
Protocol Analysis
GlycanAge — IgG Glycomics Biological Age Test appears at editorial position #3 because its proposed mechanism is analyzing the glycan profile of immunoglobulin G (IgG) — the most abundant antibody in circulation — across 24 glycan features using mass spectrometry; the IgG glycome is a direct readout of low-grade inflammatory status because sialylated, galactosylated glycans are anti-inflammatory while agalactosylated, afucosylated glycans are pro-inflammatory and increase with biological aging; the shift in glycan balance toward pro-inflammatory patterns is one of the most consistent hallmarks of inflammaging and correlates with disease risk, immune senescence, and all-cause mortality independently of standard inflammatory markers. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for GlycanAge — IgG Glycomics Biological Age Test is: strong and mechanistically distinct — GlycanAge has been validated in multiple European cohort studies and clinical trials; a landmark trial showed GlycanAge improved more rapidly than chronological age expectations in women who adopted Mediterranean diet + exercise interventions; a randomized trial in postmenopausal women showed significant GlycanAge improvement with hormone replacement therapy (HRT), providing strong clinical evidence that the test responds to meaningful biological changes; GlycanAge changes have been validated against mortality risk in the Croatian 10,001 Dalmatians cohort. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for GlycanAge — IgG Glycomics Biological Age Test are: GlycanAge measures specifically the immune aging and inflammatory axis of biological aging — it can show significant improvement from anti-inflammatory lifestyle changes while epigenetic age may change more slowly; this makes it excellent for lifestyle tracking but means it should not be used as the sole measure of overall biological aging; GlycanAge costs $300–450 and is less widely distributed than some competing services. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: adults who have already established a baseline epigenetic or phenotypic age score and want an independent, faster-responding biological age signal; particularly useful for people testing specific anti-inflammatory interventions (Mediterranean diet, omega-3, HRT in women, exercise protocols) where the glycan response will be faster and more sensitive than epigenetic methylation clocks. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Elysium Index — Second-Generation Epigenetic Clock
Elysium Index measures biological age from DNA methylation patterns in saliva or blood using a validated second-generation epigenetic clock, with results delivered through a clear dashboard showing biological age versus chronological age and lifestyle-linked insights.
Best for: Longevity-focused adults seeking an accessible, peer-reviewed epigenetic biological age test at a lower price point than TruAge Complete — Elysium Index uses a validated second-generation epigenetic clock algorithm and provides clear, actionable biological age comparison with annual retesting subscription options
Pros
- +Saliva collection — simplest sample collection of any epigenetic test, no fingerstick required
- +More accessible price point than TruAge Complete
- +Annual retesting subscription plans available — good for consistent monitoring at lower per-test cost
- +Clear, consumer-friendly dashboard with lifestyle insights
- +Solid scientific backing — peer-reviewed epigenetic clock methodology with experienced scientific advisory board
- +Good entry point for epigenetic testing without the complexity of multi-clock decomposition
Cons
- −Does not include DunedinPACE — the best-validated pace-of-aging metric — which is available in TruAge Complete
- −Single biological age estimate rather than multi-clock panel — less information per test
- −Less extensively independently peer-reviewed than the Trudiagnostic platform
- −Saliva-based methylation may have more technical noise than blood-based DNA methylation in some studies
Protocol Analysis
Elysium Index — Second-Generation Epigenetic Clock appears at editorial position #4 because its proposed mechanism is measuring DNA methylation patterns across a curated CpG site panel using a validated epigenetic clock algorithm (based on second-generation clock science in the GrimAge and DunedinPACE lineage) to generate a biological age estimate from saliva or blood; the algorithm is trained on population-level datasets linking methylation signatures to mortality, disease, and healthspan outcomes. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Elysium Index — Second-Generation Epigenetic Clock is: solid for the underlying clock science — Elysium's platform uses peer-reviewed epigenetic clock methodology and their scientific advisory board includes leading aging researchers; the platform has been less extensively independently validated than TruAge/Trudiagnostic in published peer-reviewed literature, though the underlying methylation clock approach is the same; Elysium publishes validation data showing correlation with lifestyle health behaviors and known aging markers. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Elysium Index — Second-Generation Epigenetic Clock are: Elysium Index does not include DunedinPACE (the pace-of-aging metric) — this is a meaningful limitation compared to TruAge Complete because DunedinPACE is the most validated rate-of-aging biomarker and is often more interpretable than raw biological age comparison; Elysium reports one biological age number rather than the multi-clock decomposition TruAge provides; independent third-party validation data is more limited than for the Trudiagnostic platform. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: longevity-interested adults who want a scientifically credible epigenetic biological age test at a lower entry price point than TruAge, and who prefer a simpler single-number result over the complexity of a multi-clock panel; good for annual retesting cadence where cost efficiency matters. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
InsideTracker Ultimate + InnerAge 2.0 — Biomarker Biological Age with Action Plan
InsideTracker Ultimate pairs an extensive longevity blood panel (70+ biomarkers) with a machine-learning biological age score (InnerAge 2.0), a personalized intervention dashboard, and a food and supplement recommendation engine — making it the most comprehensive translate-to-action biological age testing service.
Best for: Action-oriented longevity users who want a comprehensive blood panel alongside a biological age score and prefer a system that translates every biomarker into a specific, personalized intervention recommendation — InsideTracker is the most behaviorally actionable biological age platform available
Pros
- +Most comprehensive blood panel of any biological age service — 70+ longevity biomarkers in a single draw
- +Most actionable dashboard: specific food, supplement, and exercise recommendations per biomarker
- +Blood draw results in 2–7 days — fastest of the blood-based longevity testing services
- +Tracks biomarker trends across all retest visits — longitudinal database-building
- +Can catch clinically significant findings (Lp(a), ApoB, hormone abnormalities) alongside the biological age score
- +Personalized to individual biology rather than generic recommendations
Cons
- −Requires a clinic visit for blood draw — no at-home collection
- −Higher cost ($400–700 for Ultimate plan)
- −InnerAge 2.0 algorithm is proprietary with less published external validation than PhenoAge or epigenetic clocks
- −Recommendation overload if many biomarkers are suboptimal simultaneously
Protocol Analysis
InsideTracker Ultimate + InnerAge 2.0 — Biomarker Biological Age with Action Plan appears at editorial position #5 because its proposed mechanism is running a comprehensive blood draw at a partner lab (LabCorp or Quest) covering 70+ longevity biomarkers including ApoB, Lp(a), GGT, testosterone, cortisol, IGF-1, ferritin, full metabolic panel, thyroid, and inflammatory markers; applying the InnerAge 2.0 machine learning algorithm (trained on the InsideTracker platform database) to calculate a biological age from the biomarker composite; generating personalized intervention recommendations for food, supplements, exercise, and lifestyle changes targeted to move the most impactful biomarkers in the right direction. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for InsideTracker Ultimate + InnerAge 2.0 — Biomarker Biological Age with Action Plan is: moderate-to-strong — the InnerAge 2.0 algorithm uses a proprietary ML model trained on InsideTracker's database rather than the publicly validated NHANES or epigenetic cohort datasets used by PhenoAge and TruAge; InsideTracker publishes internal validation data but the algorithm lacks the level of independent third-party validation of PhenoAge or the epigenetic clocks; the comprehensive blood panel itself has high intrinsic value for longevity optimization regardless of the InnerAge calculation. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for InsideTracker Ultimate + InnerAge 2.0 — Biomarker Biological Age with Action Plan are: the InnerAge 2.0 biological age calculation uses a proprietary algorithm with less published external validation than PhenoAge or epigenetic clocks — the number should be treated as a relative tracking tool rather than an absolute biological age reference; the blood draw requires a clinic visit and has a $400–700 price tag for the Ultimate plan; the recommendation engine can feel overwhelming when 15+ biomarkers simultaneously show as 'needs improvement'. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: longevity-focused adults who want both a comprehensive blood panel and a biological age estimate in one service, and specifically value getting specific food, supplement, and exercise recommendations tied to their exact biomarker profile; best for people who are ready to act on detailed data rather than just want a single biological age number. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Telomere Length Testing (Life Length / RepeatDX / SpectraCell)
Telomere length testing measures the protective caps on chromosome ends as a proxy for cellular aging — shorter telomeres correlate with accelerated biological aging, higher disease risk, and reduced replicative lifespan. Life Length, RepeatDX, and SpectraCell offer clinically validated Q-FISH or qPCR telomere measurement from a blood sample.
Best for: Longevity researchers and advanced biohackers who want a direct cellular aging measurement independent of epigenetic and blood biomarker methods — telomere length provides a distinct biological aging signal reflecting cumulative cellular senescence burden, though it has significant measurement variability that limits single-test interpretability
Pros
- +Mechanistically distinct from epigenetic and biomarker aging tests — measures actual cellular telomere shortening
- +Q-FISH method (Life Length) provides both average and critically short telomere percentage — a more complete picture
- +Strong epidemiological validation linking short telomeres to mortality, CVD, and cognitive decline
- +Adds a cellular senescence dimension to a multi-test biological age assessment
- +Useful for assessing interventions specifically targeting telomere biology (exercise, sleep, anti-senolytic protocols)
Cons
- −High single-test measurement variability — wide confidence intervals make single readings difficult to interpret
- −qPCR-based lab tests (cheaper options) have lower precision than Q-FISH
- −Requires clinic blood draw
- −Slower to respond to lifestyle interventions than epigenetic clocks or GlycanAge
- −Less actionable on a per-result basis compared to PhenoAge or TruAge
Protocol Analysis
Telomere Length Testing (Life Length / RepeatDX / SpectraCell) appears at editorial position #7 because its proposed mechanism is measuring the length of telomeric DNA repeat sequences (TTAGGG) at chromosome ends via quantitative PCR (qPCR) or fluorescence in situ hybridization (Q-FISH) — as cells divide throughout life, telomeres progressively shorten; when telomeres reach a critical minimum length, cells enter senescence or apoptosis; average and minimum telomere length in circulating leukocytes serves as an integrated proxy for cumulative cellular aging, replicative capacity, and senescence burden across the immune system. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Telomere Length Testing (Life Length / RepeatDX / SpectraCell) is: moderate and improving — epidemiological studies consistently show shorter telomere length associated with higher all-cause mortality, cardiovascular disease, and cognitive decline in large cohorts; however, intra-individual variability and measurement noise are significant challenges: telomere length varies substantially across different cell types, measurement methods differ between labs, and single-test telomere values have wide confidence intervals; the strongest use case is trend tracking across multiple tests over years rather than a single-point absolute measurement. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Telomere Length Testing (Life Length / RepeatDX / SpectraCell) are: single-test telomere length has high measurement noise and should not be used to make confident clinical decisions — the confidence interval on a single test can be ±2–5 years of equivalent biological aging; qPCR-based methods (SpectraCell, some others) are cheaper but less precise than Q-FISH methods (Life Length); telomere length in blood reflects immune cell aging specifically, not whole-body aging; very short telomere length or CST% above 25% warrants specialist evaluation, but moderate-range results are difficult to interpret meaningfully in isolation. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: advanced longevity users who have already established baseline epigenetic age (TruAge), phenotypic age (PhenoAge), and inflammatory age (GlycanAge) and want a complementary cellular senescence measurement from a mechanistically distinct axis; or individuals with specific concerns about accelerated senescence, immunosenescence, or family history of accelerated aging. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Free Biological Age Calculators (Aging.ai, PhenoAge Tools, MyHealthInsights)
Free web-based biological age calculators — including Aging.ai 3.0 (ML biological age from 19 blood biomarkers), the Morgan Levine PhenoAge calculator (9 biomarkers), and similar free tools — provide a validated first biological age estimate with zero incremental cost, using blood data most people already have.
Best for: Complete beginners to biological age testing who want a free starting estimate from existing bloodwork — free online biological age calculators like Aging.ai 3.0 and the PhenoAge spreadsheet tools provide a validated first approximation that costs nothing and can be run in minutes from a standard blood panel
Pros
- +Completely free — zero incremental cost if you have existing bloodwork
- +Results available in minutes rather than weeks
- +PhenoAge is directly peer-reviewed (Cell Metabolism, 2018) and used as a standard comparator in academic aging research
- +Excellent first step for understanding biological age before committing to paid tests
- +Can be run quarterly with standard bloodwork for high-frequency free monitoring
Cons
- −Less precise than paid epigenetic or glycomics tests — treat as a rough estimate
- −Web calculator implementations vary in accuracy and may use outdated algorithms
- −Does not measure epigenetic, glycan, or telomere aging axes
- −Cannot replace comprehensive paid testing for serious longevity monitoring
Protocol Analysis
Free Biological Age Calculators (Aging.ai, PhenoAge Tools, MyHealthInsights) appears at editorial position #8 because its proposed mechanism is applying publicly available machine learning models or validated biomarker algorithms (PhenoAge, Aging.ai 3.0) to standard blood panel values to generate a biological age prediction; Aging.ai 3.0 was trained on a database of 300,000+ individuals and uses 19 routine biomarkers including CBC, CMP, cholesterol, and glucose; PhenoAge uses 9 biomarkers derived from NHANES validation; both produce biological age estimates that correlate meaningfully with mortality and disease risk in population studies. That placement is an editorial comparison, not a validated clinical score, diagnosis, treatment recommendation, or prediction of an individual outcome. The relevant question for a reader is whether the mechanism and evidence apply to the population, formulation, baseline status, medications, and outcome being considered.
The evidence profile supplied for Free Biological Age Calculators (Aging.ai, PhenoAge Tools, MyHealthInsights) is: moderate — the underlying algorithms (PhenoAge, Aging.ai 3.0) are peer-reviewed and validated in published studies; the web-based implementations vary in reliability — PhenoAge is directly from the academic paper by Levine et al. (2018) and is the most validated; Aging.ai 3.0 was published with validation data in Aging (Albany NY) and is a credible biological age estimator; other free tools have more variable scientific backing. ProtocolRank uses this material to compare evidence quality, applicability, known limitations, and practical burden. It does not convert those inputs into a clinically validated effect estimate. Where trials use different populations, formulations, endpoints, or follow-up periods, those differences can make a direct ranking less certain than the ordinal presentation suggests.
Implementation details in studies and source notes can be useful for understanding what was actually tested, but they are not a personal dosing or treatment plan. Formulation, dose, duration, baseline laboratory status, comorbidities, pregnancy status, and medication interactions can materially change the risk-benefit balance. For interventions that affect a medical condition, laboratory value, prescription therapy, or meaningful safety risk, a qualified clinician should determine whether and how the evidence applies to a specific person.
The most important limitations and cautions supplied for Free Biological Age Calculators (Aging.ai, PhenoAge Tools, MyHealthInsights) are: free calculators are entry points, not substitutes for validated paid tests — the estimates have significant noise, especially in the absence of CRP and full CBC differential; web calculators may have data entry errors or use outdated algorithm implementations; the free tools should be understood as ballpark estimates that indicate whether to invest in more comprehensive paid testing, not as standalone clinical-grade biological age assessments. These are reasons to slow down, verify assumptions, and seek appropriate review when needed; they are not instructions for self-treatment. Evidence can be directionally useful while still being too indirect, too small, or too population-specific to justify an individual intervention.
Populations or use cases discussed in the underlying literature or source notes include: anyone who wants a biological age estimate before deciding whether to invest in TruAge, GlycanAge, or InsideTracker; people who already have bloodwork but have never calculated a biological age from it; beginners to longevity testing who want to understand the concept of biological versus chronological age before committing to paid testing. That does not establish that the intervention is appropriate for a particular reader. Compare the stated evidence with your actual goal, baseline status, alternatives, contraindications, and the cost of being wrong. The safest interpretation of this ranking is as a research map for a better-informed decision, not as a protocol to copy exactly.
Implementation Playbook
- • Clarify the decision first: define the specific biological age testing — start with free PhenoAge from existing bloodwork (5 minutes, zero cost), then add TruAge Complete for epigenetic baseline (annually), then GlycanAge for lifestyle intervention tracking (every 6 months), then omega-3 index to confirm supplementation is reaching therapeutic range (before and after starting omega-3 protocol) outcome you care about and what evidence would meaningfully change your mind.
- • Check whether the evidence matches your situation: population, baseline status, formulation, comparator, duration, and outcome should be close enough to make the result relevant.
- • Separate study protocol from personal instruction. A dose, schedule, or progression used in a paper describes what was studied; it is not automatically appropriate for an individual reader.
- • Review contraindications, medication interactions, pregnancy considerations, laboratory monitoring needs, and other safety constraints before treating an intervention as actionable.
- • Prefer one clearly defined decision at a time so benefits, adverse effects, and confounders are easier to interpret. For medically consequential interventions, make that decision with a qualified clinician.
- • Predefine what would count as useful, ineffective, or concerning and when the decision should be revisited. Avoid extending an intervention simply because it was ranked highly on this site.
The Verdict
TruAge Complete (Trudiagnostic) holds the first editorial position because it provides the most scientifically comprehensive biological age readout available to consumers — 13+ validated epigenetic clock algorithms including DunedinPACE, the best-validated pace-of-aging biomarker, on the same 850K Illumina methylation array used in academic aging research — making it the only consumer test with direct comparability to the published longevity science that Sinclair, Attia, Huberman, and Bryan Johnson reference. That is a comparative judgment about the current evidence and practical context, not a prescription or a guarantee of benefit.
PhenoAge calculated from a standard blood panel is the essential no-cost complement — run it quarterly from routine bloodwork to track biological age trends between annual epigenetic tests, monitor acute interventions (diet, supplement changes), and identify the specific biomarkers (CRP, glucose, albumin, RDW) driving biological age acceleration is another option worth comparing when its evidence and constraints better match the decision at hand. the most common error is investing in expensive biological age tests without first optimizing the free, highest-return interventions — confirm your PhenoAge from existing bloodwork, check your omega-3 index ($50), and implement the foundational longevity protocols (Zone 2 training, omega-3, sleep optimization, caloric moderation) before spending $400+ on advanced epigenetic testing; the tests are most valuable when you have clean baseline interventions in place so result changes can be clearly attributed. Treat the ordering as a research aid, then verify population fit, contraindications, alternatives, and objective response with appropriate professional review when the decision is medically consequential.
Related ProtocolRank Articles
Best Longevity Protocols 2026
The top longevity protocol frameworks ranked by evidence quality, adherence, and healthspan impact — foundational context for interpreting your biological age results.
Best Longevity Blood Tests 2026
Best blood panels for longevity ranked by biomarker signal and clinical utility — the panels that supply the data for PhenoAge and InsideTracker biological age calculations.
Best Longevity Lab Testing Services Ranked 2026
Ranked comparison of longevity lab testing services for panel breadth, cost, and data clarity — useful for sourcing the blood panel underlying your PhenoAge or InnerAge calculation.
Best Omega-3 Supplements Ranked 2026
Top EPA+DHA products ranked by dose, triglyceride versus ethyl ester form, and clinical evidence — the supplement most directly improving your omega-3 index biological age biomarker.
David Sinclair vs Bryan Johnson Longevity Protocol 2026
Side-by-side comparison of the Sinclair and Bryan Johnson longevity protocols — both use epigenetic age testing as a primary feedback mechanism for intervention validation.
Rhonda Patrick Supplement Stack Ranked 2026
Dr. Rhonda Patrick's evidence-first supplement protocol — omega-3, D3+K2, sulforaphane, magnesium, creatine — the foundation for improving biological age biomarkers across multiple axes.
Best Longevity Supplements for Women Over 50 Ranked 2026
The 8 best longevity supplements for post-menopausal women ranked by healthspan evidence — directly relevant to improving GlycanAge and PhenoAge in the over-50 demographic.
Andrew Huberman vs Peter Attia Supplement Stack 2026
Huberman vs Attia protocol comparison — both practitioners use biological age proxies and biomarker tracking as core feedback mechanisms in their longevity approaches.
NMN vs NR vs NAD+ Comparison
NAD+ precursor comparison by bioavailability, human evidence, and longevity pathway activation — NMN and NR are among the most studied compounds for epigenetic age improvement in intervention trials.
Best Home Blood Test Kits Ranked 2026
At-home blood test kits ranked for the biomarkers needed for PhenoAge and biological age calculation — the easiest path to getting the bloodwork required for free biological age scoring.
Best Wearable Health Trackers for Longevity Ranked 2026
Oura Ring, WHOOP, CGM, Apple Watch, and Garmin ranked by biomarker accuracy and longevity signal coverage — the wearable data layer that works alongside biological age testing to track intervention response in real time.
Further Reading from Our Sister Sites
Alive Longevity
Alive Longevity: Longevity Supplement Guides
Research-backed supplement explainers and buyer guides for stacking decisions.
Peaked Labs
Peaked Labs: TRT Provider Comparisons
Compare telehealth TRT provider models, monitoring cadence, and total program costs.
Alive Longevity
Alive Longevity: Ingredient Deep Dives
Deep dives on high-interest ingredients like omega-3s, collagen, and magnesium forms.
Biological Age Tests 2026 — Frequently Asked Questions
What is biological age and how is it different from chronological age?
Chronological age is simply how long you have been alive in calendar years. Biological age is an estimate of how much your body has aged at the cellular, molecular, and physiological level — which can be significantly different from your chronological age depending on genetics, lifestyle, metabolic health, and accumulated stress. A 50-year-old with excellent longevity habits might have a biological age of 40 by epigenetic clock measurement, while a 50-year-old with poor metabolic health might test at 60. Biological age tests measure specific molecular signals — DNA methylation patterns, blood biomarker composites, glycan patterns, or telomere length — to estimate how much your body's aging machinery has advanced relative to population averages.
Is DunedinPACE different from epigenetic biological age?
Yes — DunedinPACE measures the pace of aging (how fast you are aging per calendar year) rather than biological age at a single point in time. A DunedinPACE score of 0.85 means you are aging approximately 15% slower than one year per calendar year — a meaningful longevity advantage. A score of 1.15 means you are aging 15% faster. This is mechanistically more informative than a raw biological age estimate because it tells you the rate, not just the current position. TruAge Complete includes DunedinPACE alongside multiple biological age clocks, which is a primary reason it ranks #1. The CALERIE trial of caloric restriction showed DunedinPACE improvement of approximately 2–3% — meaningful evidence that the metric responds to longevity interventions.
How often should I retest my biological age?
Optimal retesting cadence depends on the test type: TruAge epigenetic testing should be done once per year — epigenetic methylation patterns change slowly and annual retesting is the most cost-effective frequency. GlycanAge should be done every 6 months if you are actively implementing anti-inflammatory lifestyle interventions, since it responds faster to dietary and exercise changes. PhenoAge should be calculated quarterly from routine bloodwork — it is free and provides a higher-frequency check on your metabolic and inflammatory biological age. Omega-3 index should be tested before starting supplementation and again after 3–4 months to confirm you have reached the therapeutic 8–12% range, then annually for maintenance.
Do Bryan Johnson, David Sinclair, and Peter Attia use biological age tests?
Yes. Bryan Johnson's Blueprint protocol uses epigenetic age testing as a primary outcome metric — his team publishes his biological age results quarterly and uses DunedinPACE as a core intervention tracking tool. David Sinclair has publicly discussed using epigenetic age testing and PhenoAge in his research and personal longevity practice. Peter Attia uses comprehensive blood biomarker panels with phenotypic age scoring and emphasizes ApoB, insulin, and metabolic biomarkers as biological age proxies. All three use biological age testing not as novelty but as the primary feedback mechanism for whether their longevity protocols are actually working at the molecular level.
Can lifestyle changes actually reduce biological age?
Yes, with meaningful effect sizes in published research. The CALERIE randomized trial of 25% caloric restriction showed DunedinPACE reduction of approximately 2–3% — equivalent to aging noticeably slower. Exercise interventions (especially aerobic training + resistance training combination) show consistent epigenetic age improvement in RCTs. GlycanAge improved significantly in randomized trials of Mediterranean diet and hormone replacement therapy in postmenopausal women. PhenoAge improves reliably with interventions that reduce CRP, improve glucose, and normalize albumin. The most consistent lifestyle biological age improvers across all test types are: aerobic exercise (Zone 2 training), sleep optimization (7–9 hours, consistent schedule), omega-3 supplementation to reach 8–12% index, and caloric moderation without severe restriction.
Is epigenetic age testing worth the $350–500 cost?
It depends on how you use it. If you take one test, look at the number, and change nothing, the value is low. If you use it as a baseline before beginning a structured longevity protocol, retest at 12 months to measure DunedinPACE change, and treat the result as accountability data for your intervention stack, the value is high. At $350–500 for an annual TruAge Complete test, the per-day cost is roughly $1–1.40 — less than a cup of coffee. The practical test is whether you would pay $1/day to know whether your longevity interventions are actually working at the molecular level. Most serious longevity practitioners find this a reasonable trade-off. If cost is a barrier, start with free PhenoAge from existing bloodwork and the $50–80 omega-3 index before committing to epigenetic testing.
What biological age test should I start with as a beginner?
Start free: calculate your PhenoAge from your most recent blood panel using an online calculator (free, 5 minutes). If you have a CBC with differential and a CMP plus CRP, you have everything you need. This gives you a validated biological age estimate from peer-reviewed science at zero cost. Step two: test your omega-3 index ($50–80, at-home fingerstick) — most people in the US test at 4–6% when the longevity-protective range is 8–12%, and this is the most directly fixable biological aging driver available. Step three: once you have baseline interventions in place, invest in TruAge Complete ($350–500) for your annual epigenetic biological age measurement. This three-step protocol covers the free, cheap, and premium biological age assessment tiers without starting with the most expensive option.
How do I interpret a biological age test result that is older than my chronological age?
A biological age older than chronological age — sometimes called 'biological age acceleration' — is common and does not mean you are condemned to early death. It means there are specific molecular or physiological systems aging faster than average for your calendar age, and most of those drivers are modifiable. For epigenetic tests: look at which specific clocks are most elevated (GrimAge reflects inflammation and smoking exposure; FitAge reflects fitness; immune clocks reflect senescence burden). For PhenoAge: identify which of the 9 biomarkers are out of optimal range — CRP, glucose, and RDW are the most commonly elevated and the most modifiable. For GlycanAge: an older glycan age points specifically to the inflammatory axis — anti-inflammatory diet, omega-3 supplementation, exercise, and stress reduction are the highest-leverage interventions. The useful interpretation is not 'I am X years old biologically' but 'which specific aging pathways are accelerated and what can I do about them.'